XM
IRWD icon

XTX Markets’s Ironwood Pharmaceuticals IRWD Stock Holding History

XTX Markets’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,945
Closed -$170K – 217
2020
Q3 		$170K Buy
+18,945
New +$188K 0.82% 68

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

XTX Markets's IRWD Position: Q4 2020 in Review

XTX Markets sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2020, closing a stake of 18,945 shares — an estimated $170K sold.

XTX Markets first reported a position in IRWD in Q3 2020 and held it in 1 quarter. The position peaked at $170K in Q3 2020. 199 funds tracked by Wall St. Rank hold IRWD as of Q4 2020.

  • XTX Markets reported no remaining Ironwood Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • XTX Markets sold 18,945 Ironwood Pharmaceuticals shares in Q4 2020, an estimated $170K.
  • XTX Markets first reported a position in Ironwood Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • XTX Markets's Ironwood Pharmaceuticals position peaked at $170K in Q3 2020.
  • 199 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.